Franklin Wright
Concepts (204)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Wounds and Injuries | 20 | 2026 | 959 | 2.320 |
Why?
| | Blood Transfusion | 10 | 2025 | 394 | 1.330 |
Why?
| | Trauma Centers | 8 | 2026 | 441 | 1.300 |
Why?
| | Resuscitation | 6 | 2024 | 314 | 1.000 |
Why?
| | Venous Thromboembolism | 3 | 2025 | 332 | 0.880 |
Why?
| | Hemorrhage | 5 | 2025 | 825 | 0.850 |
Why?
| | Blood Component Transfusion | 4 | 2025 | 99 | 0.820 |
Why?
| | Venous Thrombosis | 2 | 2025 | 199 | 0.790 |
Why?
| | Hypocalcemia | 4 | 2026 | 40 | 0.740 |
Why?
| | Shock, Hemorrhagic | 3 | 2024 | 195 | 0.690 |
Why?
| | Altitude | 1 | 2025 | 469 | 0.640 |
Why?
| | Blood Coagulation Tests | 1 | 2020 | 72 | 0.610 |
Why?
| | Stroke | 3 | 2026 | 1287 | 0.600 |
Why?
| | Trauma Severity Indices | 1 | 2019 | 115 | 0.580 |
Why?
| | Thromboembolism | 1 | 2020 | 129 | 0.570 |
Why?
| | Injury Severity Score | 8 | 2026 | 572 | 0.570 |
Why?
| | Extremities | 1 | 2019 | 142 | 0.560 |
Why?
| | Fibrinolysis | 1 | 2020 | 162 | 0.550 |
Why?
| | Plasma | 1 | 2018 | 222 | 0.500 |
Why?
| | Triage | 1 | 2018 | 243 | 0.470 |
Why?
| | Oxygen | 3 | 2026 | 997 | 0.440 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 387 | 0.430 |
Why?
| | Coronavirus Infections | 1 | 2020 | 379 | 0.430 |
Why?
| | Oxygen Inhalation Therapy | 2 | 2026 | 190 | 0.400 |
Why?
| | England | 4 | 2026 | 106 | 0.400 |
Why?
| | Transfusion Reaction | 2 | 2025 | 61 | 0.380 |
Why?
| | Adult | 29 | 2026 | 41087 | 0.370 |
Why?
| | Interleukin-1beta | 1 | 2014 | 397 | 0.370 |
Why?
| | Quality Improvement | 6 | 2025 | 1354 | 0.370 |
Why?
| | Myocardial Infarction | 2 | 2017 | 1215 | 0.360 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2014 | 1224 | 0.350 |
Why?
| | Middle Aged | 24 | 2026 | 36619 | 0.350 |
Why?
| | Cardiovascular Diseases | 1 | 2023 | 2219 | 0.320 |
Why?
| | Retrospective Studies | 15 | 2026 | 17438 | 0.300 |
Why?
| | Hypoxia | 3 | 2026 | 1211 | 0.300 |
Why?
| | Hospitalization | 3 | 2026 | 2475 | 0.300 |
Why?
| | Heart Failure | 1 | 2023 | 2329 | 0.300 |
Why?
| | Calcium | 3 | 2026 | 1181 | 0.300 |
Why?
| | Tissue Plasminogen Activator | 2 | 2021 | 245 | 0.300 |
Why?
| | Pandemics | 3 | 2023 | 1707 | 0.280 |
Why?
| | Male | 29 | 2026 | 73396 | 0.270 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1432 | 0.270 |
Why?
| | Saline Solution, Hypertonic | 3 | 2014 | 43 | 0.270 |
Why?
| | Thoracostomy | 2 | 2026 | 26 | 0.260 |
Why?
| | Humans | 39 | 2026 | 146342 | 0.250 |
Why?
| | Female | 27 | 2026 | 79499 | 0.250 |
Why?
| | ABO Blood-Group System | 2 | 2024 | 56 | 0.250 |
Why?
| | Hemothorax | 1 | 2026 | 19 | 0.240 |
Why?
| | Registries | 3 | 2024 | 2400 | 0.240 |
Why?
| | Thoracic Surgery, Video-Assisted | 1 | 2026 | 55 | 0.230 |
Why?
| | Hypercalcemia | 1 | 2026 | 23 | 0.230 |
Why?
| | Electronic Health Records | 2 | 2025 | 1210 | 0.230 |
Why?
| | Aged | 17 | 2026 | 26432 | 0.230 |
Why?
| | Wounds, Penetrating | 2 | 2019 | 71 | 0.220 |
Why?
| | Sex Distribution | 3 | 2026 | 382 | 0.210 |
Why?
| | Wound Infection | 1 | 2025 | 60 | 0.210 |
Why?
| | Liver Transplantation | 3 | 2024 | 751 | 0.210 |
Why?
| | Antibiotic Prophylaxis | 1 | 2025 | 140 | 0.200 |
Why?
| | Vital Signs | 1 | 2024 | 39 | 0.200 |
Why?
| | Partial Thromboplastin Time | 2 | 2021 | 53 | 0.200 |
Why?
| | Airway Management | 1 | 2024 | 84 | 0.200 |
Why?
| | Lung | 2 | 2014 | 4122 | 0.200 |
Why?
| | Western Australia | 2 | 2026 | 8 | 0.190 |
Why?
| | Inflammation | 1 | 2014 | 2919 | 0.190 |
Why?
| | Hemostatics | 1 | 2004 | 66 | 0.190 |
Why?
| | Propensity Score | 1 | 2025 | 376 | 0.190 |
Why?
| | Aged, 80 and over | 6 | 2026 | 8391 | 0.190 |
Why?
| | Wounds, Gunshot | 2 | 2019 | 262 | 0.180 |
Why?
| | Age Distribution | 2 | 2026 | 399 | 0.180 |
Why?
| | Pulmonary Embolism | 1 | 2024 | 246 | 0.170 |
Why?
| | Intubation, Intratracheal | 1 | 2024 | 330 | 0.170 |
Why?
| | Advance Directives | 1 | 2022 | 89 | 0.160 |
Why?
| | Risk Factors | 6 | 2025 | 10921 | 0.160 |
Why?
| | Fibrin Clot Lysis Time | 1 | 2020 | 10 | 0.160 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2020 | 92 | 0.150 |
Why?
| | Feasibility Studies | 1 | 2024 | 1135 | 0.150 |
Why?
| | Thrombelastography | 1 | 2020 | 182 | 0.140 |
Why?
| | Sepsis | 1 | 2025 | 669 | 0.140 |
Why?
| | NF-kappa B | 2 | 2014 | 674 | 0.140 |
Why?
| | Cerebrovascular Disorders | 1 | 2019 | 103 | 0.130 |
Why?
| | Critical Illness | 2 | 2021 | 908 | 0.130 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 330 | 0.130 |
Why?
| | Thrombosis | 1 | 2021 | 398 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 288 | 0.130 |
Why?
| | Clinical Protocols | 1 | 2018 | 282 | 0.120 |
Why?
| | Time Factors | 4 | 2026 | 7109 | 0.120 |
Why?
| | Information Storage and Retrieval | 1 | 2017 | 121 | 0.120 |
Why?
| | Sensitivity and Specificity | 2 | 2019 | 1998 | 0.120 |
Why?
| | Emergency Medical Services | 2 | 2024 | 680 | 0.120 |
Why?
| | Postoperative Complications | 2 | 2026 | 3034 | 0.120 |
Why?
| | Renal Dialysis | 1 | 2020 | 461 | 0.120 |
Why?
| | Military Personnel | 1 | 2024 | 726 | 0.120 |
Why?
| | Violence | 1 | 2019 | 275 | 0.120 |
Why?
| | Epithelial Cells | 2 | 2014 | 1119 | 0.110 |
Why?
| | Emergency Service, Hospital | 2 | 2026 | 2363 | 0.110 |
Why?
| | Regression Analysis | 1 | 2017 | 999 | 0.110 |
Why?
| | Anti-Bacterial Agents | 1 | 2025 | 1942 | 0.100 |
Why?
| | Transcription Factor RelA | 1 | 2014 | 93 | 0.100 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2113 | 0.100 |
Why?
| | Intensive Care Units | 1 | 2020 | 925 | 0.100 |
Why?
| | Oximetry | 2 | 2026 | 124 | 0.090 |
Why?
| | Matrix Metalloproteinase 13 | 1 | 2012 | 25 | 0.090 |
Why?
| | Incidence | 4 | 2026 | 2936 | 0.090 |
Why?
| | Phosphorylation | 2 | 2014 | 1724 | 0.090 |
Why?
| | Reoperation | 2 | 2026 | 645 | 0.090 |
Why?
| | Cell Line | 2 | 2014 | 2814 | 0.080 |
Why?
| | Prospective Studies | 4 | 2026 | 8123 | 0.080 |
Why?
| | Young Adult | 6 | 2025 | 14330 | 0.080 |
Why?
| | Colorado | 1 | 2019 | 4595 | 0.070 |
Why?
| | Acute Lung Injury | 1 | 2012 | 312 | 0.070 |
Why?
| | Guideline Adherence | 2 | 2025 | 594 | 0.070 |
Why?
| | Hepatitis, Autoimmune | 1 | 2008 | 11 | 0.070 |
Why?
| | Survivors | 1 | 2012 | 526 | 0.070 |
Why?
| | Liver Failure | 1 | 2008 | 79 | 0.070 |
Why?
| | British Columbia | 1 | 2026 | 27 | 0.060 |
Why?
| | New Zealand | 1 | 2026 | 56 | 0.060 |
Why?
| | Ontario | 1 | 2026 | 91 | 0.060 |
Why?
| | Respiration, Artificial | 2 | 2022 | 711 | 0.060 |
Why?
| | Thoracotomy | 1 | 2026 | 87 | 0.060 |
Why?
| | Adolescent | 6 | 2025 | 22557 | 0.060 |
Why?
| | Adrenal Cortex Hormones | 1 | 2008 | 486 | 0.050 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2025 | 37 | 0.050 |
Why?
| | United States Department of Defense | 1 | 2024 | 26 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2026 | 417 | 0.050 |
Why?
| | Data Interpretation, Statistical | 1 | 2026 | 368 | 0.050 |
Why?
| | Mortality | 1 | 2026 | 375 | 0.050 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2007 | 370 | 0.050 |
Why?
| | Acute Disease | 1 | 2026 | 1038 | 0.050 |
Why?
| | Calcium, Dietary | 1 | 2023 | 52 | 0.050 |
Why?
| | Tracheostomy | 1 | 2024 | 136 | 0.050 |
Why?
| | Treatment Outcome | 4 | 2024 | 11821 | 0.040 |
Why?
| | Signal Transduction | 1 | 2014 | 5246 | 0.040 |
Why?
| | Infant | 3 | 2024 | 10114 | 0.040 |
Why?
| | Liver Neoplasms | 1 | 2007 | 776 | 0.040 |
Why?
| | Patient Outcome Assessment | 1 | 2021 | 129 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2021 | 5439 | 0.040 |
Why?
| | Child, Preschool | 3 | 2024 | 11913 | 0.040 |
Why?
| | Hyperoxia | 1 | 2021 | 126 | 0.040 |
Why?
| | Anticoagulants | 1 | 2025 | 746 | 0.040 |
Why?
| | Research Design | 1 | 2026 | 1143 | 0.040 |
Why?
| | Survival Rate | 1 | 2024 | 2092 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2026 | 1763 | 0.040 |
Why?
| | World Health Organization | 1 | 2019 | 104 | 0.040 |
Why?
| | Homicide | 1 | 2019 | 65 | 0.030 |
Why?
| | Fibrinolytic Agents | 1 | 2021 | 303 | 0.030 |
Why?
| | Databases, Factual | 1 | 2024 | 1493 | 0.030 |
Why?
| | Europe | 1 | 2019 | 421 | 0.030 |
Why?
| | Terminal Care | 1 | 2022 | 284 | 0.030 |
Why?
| | Obesity | 2 | 2024 | 3131 | 0.030 |
Why?
| | Decision Support Systems, Clinical | 1 | 2021 | 279 | 0.030 |
Why?
| | Intracranial Hemorrhages | 1 | 2018 | 106 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2025 | 1591 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2022 | 1051 | 0.030 |
Why?
| | United Kingdom | 1 | 2018 | 377 | 0.030 |
Why?
| | Length of Stay | 1 | 2022 | 1358 | 0.030 |
Why?
| | Pilot Projects | 1 | 2021 | 1888 | 0.030 |
Why?
| | Child | 3 | 2024 | 22693 | 0.030 |
Why?
| | Life Style | 1 | 2018 | 496 | 0.030 |
Why?
| | Decision Making | 1 | 2022 | 993 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2019 | 6460 | 0.030 |
Why?
| | Brain Ischemia | 1 | 2018 | 362 | 0.030 |
Why?
| | United States | 2 | 2024 | 16136 | 0.030 |
Why?
| | Immunosuppressive Agents | 2 | 2008 | 829 | 0.020 |
Why?
| | Nebulizers and Vaporizers | 1 | 2012 | 63 | 0.020 |
Why?
| | Neutrophil Infiltration | 1 | 2012 | 107 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2012 | 183 | 0.020 |
Why?
| | Medical Record Linkage | 1 | 2012 | 68 | 0.020 |
Why?
| | Random Allocation | 1 | 2012 | 366 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2012 | 567 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2024 | 6073 | 0.020 |
Why?
| | Secondary Prevention | 1 | 2012 | 248 | 0.020 |
Why?
| | Smoking | 1 | 2018 | 1486 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2021 | 5899 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2012 | 970 | 0.020 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2012 | 642 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2018 | 1101 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2012 | 1331 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1712 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2012 | 1327 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2009 | 404 | 0.020 |
Why?
| | Protein Transport | 1 | 2009 | 443 | 0.020 |
Why?
| | Comorbidity | 1 | 2012 | 1665 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2012 | 2537 | 0.020 |
Why?
| | Blotting, Western | 1 | 2009 | 1177 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2008 | 778 | 0.020 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2007 | 88 | 0.010 |
Why?
| | Blood Vessels | 1 | 2007 | 164 | 0.010 |
Why?
| | Cell Survival | 1 | 2009 | 1105 | 0.010 |
Why?
| | Neoplasm Invasiveness | 1 | 2007 | 504 | 0.010 |
Why?
| | Sirolimus | 1 | 2007 | 282 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2009 | 1163 | 0.010 |
Why?
| | Recurrence | 1 | 2008 | 1133 | 0.010 |
Why?
| | Age Factors | 1 | 2012 | 3347 | 0.010 |
Why?
| | Preoperative Care | 1 | 2007 | 396 | 0.010 |
Why?
| | Survival Analysis | 1 | 2007 | 1378 | 0.010 |
Why?
| | Rats | 1 | 2012 | 5586 | 0.010 |
Why?
| | Prognosis | 1 | 2012 | 4351 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 2007 | 1488 | 0.010 |
Why?
| | Risk Assessment | 1 | 2012 | 3712 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2012 | 4580 | 0.010 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2007 | 1160 | 0.010 |
Why?
| | Liver | 1 | 2007 | 1864 | 0.010 |
Why?
| | Cohort Studies | 1 | 2008 | 6077 | 0.010 |
Why?
| | Animals | 1 | 2012 | 38107 | 0.000 |
Why?
|
|
Wright's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|